Latest Non Dilutive Funding News

Zelira Therapeutics has locked in a $650,000 loan facility secured against its anticipated FY25 R&D tax rebate, aiming to accelerate its HOPE SPV clinical trial and strengthen working capital.

Argenica Therapeutics has dosed the final patient in its Phase 2 trial for ARG-007 in acute ischaemic stroke, with topline results expected in Q3 2025. Meanwhile, the FDA has placed a clinical hold on its US trial application, introducing uncertainty for US development.

Nyrada Inc. is set to launch a Phase IIa clinical trial of Xolatryp™, aiming to reduce heart muscle damage in acute myocardial infarction patients undergoing PCI. The trial, planned for early 2026, follows promising Phase I safety results and strong preclinical cardioprotection data.

4DMedical has renewed its three-year contract with the University of Michigan Medical Center, reinforcing its foothold in US respiratory imaging. Alongside, a pivotal clinical study validates its technology’s ability to detect early lung disease, while a substantial Australian grant boosts its AI research.

Revolver Resources has completed critical engineering designs and secured over A$1 million in government grants and royalties, setting the stage for a targeted restart of copper production at its Dianne Copper Mine in late 2025.

Great Dirt Resources has secured a significant exploration licence in the Pilbara lithium province and bolstered its finances with a $335,000 R&D tax rebate, setting the stage for accelerated exploration activities.

South Harz Potash Limited has launched a two-tranche placement and a rights issue to raise over A$3 million, aiming to accelerate development of its German potash assets amid mixed funding prospects.

MTM Critical Metals has appointed Gregory L. Bowman, a seasoned U.S. defense and industrial strategy expert, to the advisory board of its U.S. subsidiary Flash Metals USA, aiming to accelerate its critical metals refining technology and deepen ties with U.S. government stakeholders.

Trigg Minerals has raised A$12.5 million from institutional and strategic investors to accelerate development of its Antimony Canyon Project in Utah, positioning itself as a key supplier in the US critical minerals market amid soaring antimony prices.

Latitude 66 Limited has agreed to sell its 17.5% stake in the Greater Duchess Copper Gold Joint Venture for an upfront $2 million, with potential for additional contingent payments. The deal includes a $750,000 loan to support ongoing projects in Finland and Western Australia.

Rhythm Biosciences has obtained a $1 million non-dilutive loan backed by its FY2025 R&D Tax Incentive rebate, aiming to accelerate the commercial rollout of its ColoSTAT® test and expand its geneType™ platform.

Actinogen Medical has locked in up to $13.8 million in non-dilutive funding tied to its R&D tax incentives, bolstering its cash position as it advances a pivotal Alzheimer’s disease clinical trial.